BLAINJECTIONINJECTABLE
Approved
Nov 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ABRILADA (adalimumab-afzb) is a Pfizer biosimilar of Humira (adalimumab), a TNF-alpha inhibitor monoclonal antibody approved in 2019. It is used to treat multiple autoimmune and inflammatory conditions including rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. The drug works by binding to and neutralizing tumor necrosis factor-alpha, a key inflammatory cytokine.
Peak
As a biosimilar at peak lifecycle, ABRILADA operates in a mature, highly competitive market with established market penetration; commercial teams focus on managed care access and payer contracting rather than broad expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ABRILADA offers exposure to biosimilar commercialization, payer negotiations, and market access strategy in a competitive, mature segment. Roles emphasize managed care relationships, formulary placement, and competitive contracting rather than discovery or early-stage development.
Brand ManagerSenior Medical Science Liaison
Worked on ABRILADA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.